Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gliwice
Clinical trial register · Poland

Clinical Trials in Gliwice, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2709 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2709
Studies in scope
all four open statuses
1380
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 1318 Krakow 881 Poznan 697 Gdansk 663 Lodz 618
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC20 Maria Sklodowska-Curie National Research Institute of Oncology11 AstraZeneca10 Hoffmann-La Roche9 Janssen Research & Development, LLC7 Novartis Pharmaceuticals6 Exelixis4 Amgen3 GlaxoSmithKline3 Bristol-Myers Squibb2 Astellas Pharma Global Development, Inc.2 Genmab2 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2 Kartos Therapeutics, Inc.2 BioNTech SE2 Pfizer2 Gilead Sciences2 Cogent Biosciences, Inc.1 National Institute of Oncology, Hungary1 Regeneron Pharmaceuticals1 Ryvu Therapeutics SA1 European Organisation for Research and Treatment of Cancer - EORTC1 Nykode Therapeutics ASA1 BioInvent International AB1 Eikon Therapeutics1 Show all 49
Site location
Warsaw1318 Krakow881 Poznan697 Gdansk663 Lodz618 Wroclaw526 Bydgoszcz525 Lublin525 Katowice510 Bialystok388 Olsztyn190 Rzeszów183 Szczecin183 Gdynia167 Gliwice121 Kielce117 Torun111 Opole106 Koszalin84 Siedlce81 Zabrze69 Elblag67 Otwock56 Przemyśl55 Chorzów53 Show all 264
All 264 locations
Target enrolment
to

Trials with a site in Gliwice

121 of 2709 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
2026-09-24
Recruiting
CSL Behring
Phase 3
63
Torun, Krakow, Gliwice, Katowice, Skorzewo (Poznan)
2026-09-15
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
2026-06-26
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
UNICANCER
Phase 3
3,380
Gdansk, Gliwice, Lodz, Opole, Poznan, Szczecin, Warsaw
2026-06-26
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Krakow, Warsaw, Gliwice, Katowice
2026-05-03
Recruiting
Amgen
Phase 1
160
Gdansk, Gliwice
2026-04-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Skórzewo, Krakow, Siedlce, Warsaw, Gliwice
2026-04-09
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Not applicable
366
Gliwice
2026-03-23
Recruiting
AstraZeneca
Phase 3
508
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2026-02-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Warsaw, Gliwice, Siedlce, Kielce
2026-01-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Krakow, Warsaw, Wieliszew, Opole, Brzozów, Gdansk, Gliwice, Koszalin
2025-12-31
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Gdansk, Gliwice, Lodz, Lublin, Poznan, Warsaw
2025-12-03
Recruiting
Hoffmann-La Roche
Phase 3
250
Krakow, Bielsko-Biala, Bydgoszcz, Gliwice, Lódz, Lublin, Olsztyn
2025-11-27
Recruiting
Debiopharm International SA
Phase 3
119
Bydgoszcz, Gliwice, Krakow, Poznan, Wroclaw
2025-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Przemyśl, Gliwice, Olsztyn
2025-10-08
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Gdansk, Bytom, Gliwice, Lodz
2025-09-04
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Gdansk, Gliwice, Mysłowice, Otwock
2025-08-19
Recruiting
GlaxoSmithKline
Phase 3
420
Gliwice, Kielce, Lodz, Olsztyn, Otwock, Poznan, Przemyśl, Siedlce
2025-08-11
Recruiting
AstraZeneca
Phase 3
700
Gdynia, Gliwice, Koszalin, Krakow, Piotrkow Trybunalski, Poznan, Rzeszów, Warsaw
2025-08-06
Recruiting
Pfizer
Phase 3
714
Poznan, Lublin, Warsaw, Gdansk, Gliwice, Lodz
2025-07-23
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Gliwice, Katowice, Krakow, Warsaw, Wroclaw
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Poznan, Warsaw, Rzeszów, Gliwice, Koszalin
2025-07-16
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Bytom, Gliwice
2025-07-14
Recruiting
National Institute of Oncology, Hungary
Not applicable
250
Bialystok, Brzozów, Gliwice, Poznan, Wroclaw
2025-07-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Gdansk, Gliwice, Krakow, Poznan, Warsaw
2025-05-30
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Lubin, Warsaw, Brzozów, Gliwice, Olsztyn, Przemyśl, Swidnica
2025-05-22
Recruiting
Eikon Therapeutics
Phase 2/3
740
Gdansk, Konin, Siedlce, Gliwice, Warsaw
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Poznan, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Kielce
2025-05-22
Recruiting
GlaxoSmithKline
Phase 1/2
305
Bialystok, Gliwice, Józefów, Warsaw
2025-03-04
Active, closed
NovoCure GmbH
Phase 3
741
Bydgoszcz, Gliwice, Lodz
2025-02-03
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Gdansk, Gliwice, Katowice, Konin, Krakow, Siedlce, Warsaw
2025-01-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Wroclaw, Lublin, Warsaw, Słupsk, Gliwice, Katowice, Olsztyn
2025-01-27
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
200
Gliwice
2025-01-09
Recruiting
BioNTech SE
Phase 2/3
1,580
Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow
2025-01-07
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Gliwice, Krakow, Lublin, Poznan, Warsaw
2024-12-17
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
42
Gliwice
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole
2024-12-12
Recruiting
Ryvu Therapeutics SA
Phase 2
178
Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Gliwice, Katowice, Krakow, Olsztyn
2024-12-05
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole
2024-10-18
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Krakow, Warsaw, Gdansk, Gliwice
2024-10-14
Active, closed
Genmab
Phase 3
699
Bydgoszcz, Gdansk, Gliwice, Krakow, Lodz, Warsaw
2024-09-25
Active, closed
Amgen
Phase 1
49
Gdansk, Gliwice, Krakow, Lodz, Lublin
2024-09-17
Recruiting
AstraZeneca
Phase 3
1,018
Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-07
Active, closed
Genmab
Phase 3
621
Bydgoszcz, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Ostrów Wielkopolski, Chrzanów, Wroclaw, Puławy, Rzeszów, Gdynia, Dąbrowa Górnicza, Gliwice
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bydgoszcz, Krakow, Warsaw, Wieliszew, Bialystok, Gdynia, Gliwice, Szczecin
2024-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Bydgoszcz, Warsaw, Bialystok, Gliwice
2024-06-11
Active, closed
Exelixis
Phase 2/3
600
Piotrków, Gliwice, Torun
2024-06-07
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
450
Gliwice, Konin, Piotrkow Trybunalski
2024-05-14
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
Gdansk, Gliwice, Warsaw
2024-04-22
Recruiting
Silesian Centre for Heart Diseases
Phase 4
600
Opole, Gliwice, Zabrze, Kielce
2024-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bydgoszcz, Siedlce, Warsaw, Wieliszew, Rzeszów, Bialystok, Gdynia, Gliwice
2024-04-14
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
78
Gliwice
2024-04-11
Recruiting
GlaxoSmithKline
Phase 3
864
Bielsko-Biala, Gliwice, Katowice, Olsztyn, Przemyśl, Siedlce, Warsaw
2024-03-21
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Bydgoszcz, Gliwice
2024-01-11
Recruiting
Nykode Therapeutics ASA
Phase 1/2
110
Gdansk, Gliwice
2023-12-19
Recruiting
AstraZeneca
Phase 3
1,145
Bialystok, Bielsko-Biala, Bydgoszcz, Gliwice, Olsztyn, Piotrkow Trybunalski, Siedlce, Tomaszów Mazowiecki
2023-12-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Krakow, Lublin, Warsaw, Gdansk, Słupsk, Gliwice, Katowice, Olsztyn
2023-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,050
?ód?, Bydgoszcz, Gdynia, Gliwice, Kielce, Konin, Koszalin, Lublin
2023-12-11
Recruiting
Amgen
Phase 3
750
Bialystok, Bystra, Gdynia, Gliwice, Krakow, Lodz, Lublin, Poznan
2023-11-16
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Gliwice
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Bydgoszcz, Torun, Warsaw, Przemyśl, Gliwice, Kielce
2023-11-12
Recruiting
LeonaBio
Phase 3
600
Biała Podlaska, Gliwice, Krakow, Lodz, Poznan, Wieliszew
2023-10-31
Active, closed
Celgene
Phase 3
79
Lublin, Warsaw, Gliwice, Gdansk, Poznan
2023-10-16
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Poznan, Gliwice, Gdansk, Lodz
2023-10-02
Recruiting
AstraZeneca
Phase 3
800
Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2023-09-22
Recruiting
Hoffmann-La Roche
Phase 3
230
Bydgoszcz, Gda?sk, Gdynia, Gliwice, Konin, Koszalin, Późna, Warsaw
2023-09-08
Recruiting
Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
NCT06201078Local Recurrence of Malignant Tumor of Prostate, Radiotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
55
Gliwice
2023-07-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Poznan, Bydgoszcz, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Szczecin
2023-07-19
Recruiting
Kartos Therapeutics, Inc.
Phase 2/3
268
Bialystok, Gdansk, Gliwice, Krakow, Olsztyn, Poznan, Warsaw, Wroclaw
2023-07-17
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Bydgoszcz, Gdansk, Gliwice, Katowice, Lublin, Warsaw, Lodz
2023-06-22
Recruiting
Hoffmann-La Roche
Phase 3
420
Bydgoszcz, Gdynia, Gliwice, Konin, Koszalin, Krakow, Rzeszów, Warsaw
2023-06-07
Active, closed
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
24
Gliwice, Krakow, Poznan, Warsaw
2023-01-31
Recruiting
AstraZeneca
Phase 2
454
Gliwice, Krakow, Lodz, Poznan, Warsaw
2022-09-06
Active, closed
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT04711135Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera
Advanced Accelerator Applications
Phase 2
11
Gliwice
2022-08-31
Active, closed
Gilead Sciences
Phase 3
443
Gdansk, Gliwice, Opole, Poznan, Siedlce, Warsaw
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
Gdansk, Gliwice, Opole, Siedlce, Warsaw
2022-07-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
Warsaw, Gdansk, Gliwice, Lodz
2022-07-14
Active, closed
Pierre Fabre Medicament
Phase 3
815
Gliwice, Konin, Krakow, Poznan, Skórzewo, Warsaw, Wroclaw
2022-05-02
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Brzozów, Bydgoszcz, Gliwice, Warsaw
2022-04-14
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Lodz, Gliwice, Gdansk, Opole
2022-03-07
Active, closed
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
240
Gliwice, Krakow, Poznan, Wieliszew
2022-03-01
Active, closed
AstraZeneca
Phase 3
791
Bialystok, Gliwice, Katowice, Lodz, Warsaw, Wroclaw
2022-02-18
Active, closed
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
NCT05992610Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
Maria Sklodowska-Curie National Research Institute of Oncology
Not applicable
40
Gliwice
2022-02-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Poznan, Lublin, Siedlce, Warsaw, Bialystok, Gliwice, Kielce
2022-02-03
Not yet open
Medical University of Gdansk
Phase 2
126
Poznan, Wroclaw, Warsaw, Opole, Gdansk, Gliwice
2022-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Poznan, Warsaw, Bialystok, Gdansk, Gliwice, Kielce
2021-12-13
Active, closed
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
40
Gliwice
2021-10-07
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Bydgoszcz, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin, Poznan
2021-08-27
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
32
Bialystok, Gdansk, Gliwice, Kielce
2021-08-26
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2021-08-19
Recruiting
medac GmbH
Phase 3
210
Wroclaw, Gliwice
2021-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Przemyśl, Bialystok, Gliwice
2021-06-18
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Gliwice, Krakow, Warsaw
2021-06-09
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Bialystok, Gda?sk, Gliwice, Krakow, Poznan, Warsaw
2021-05-04
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Gliwice
2021-03-04
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Gdansk, Gliwice, Krakow, Wroclaw
2021-02-23
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Gdansk, Gliwice, Poznan, Warsaw, Wroclaw
2021-02-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Poznan, Siedlce, Warsaw, Bialystok, Gliwice, Olsztyn, Kielce
2021-01-10
Active, closed
BioNTech SE
Phase 2/3
358
Gdansk, Gliwice, Konin, Wroclaw
2021-01-07
Active, closed
Hoffmann-La Roche
Phase 2
303
Bialystok, Gliwice, Warsaw
2020-11-27
Recruiting
BioInvent International AB
Phase 1/2
197
Gliwice, Katowice, Lodz
2020-06-29
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Gdansk, Gliwice, Poznan, Warsaw
2020-06-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Gliwice, Kielce
2020-02-11
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Gliwice, Konin, Warsaw
2020-01-29
Active, closed
Pfizer
Phase 3
1,068
Gliwice, Grudziądz, Mysłowice, Piotrkow Trybunalski, Poznan, Skierniewice, Warsaw, Wroclaw
2019-12-30
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Not applicable
80
Gliwice
2019-10-26
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Gliwice, Krakow, Poznan, Warsaw
2019-06-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Krakow, Warsaw, Gdynia, Gliwice, Lodz
2018-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Warsaw, Bialystok, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin
2018-12-07
Active, closed
Exelixis
Phase 3
187
Poznan, Warsaw, Gliwice
2018-10-05
Recruiting
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
DrugsMitotane·Cis-platinum·CDDP·Etoposide
M.D. Anderson Cancer Center
Phase 3
240
Gliwice
2018-08-20
Active, closed
BeiGene
Phase 3
590
Brzozów, Chorzów, Gdansk, Gdynia, Gliwice, Krakow, Legnica, Lodz
2017-10-31
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
4,975
Gdansk, Gliwice, Poznan, Warsaw
2017-05-03
Active, closed
ITM Solucin GmbH
Phase 3
324
Gliwice, Warsaw
2017-02-02
Active, closed
Functional Abdominal Wall Reconstruction
NCT06928974Prune Belly Syndrome
Maria Sklodowska-Curie National Research Institute of Oncology
Observational
7
Gliwice
2017-01-01
Active, closed
Hoffmann-La Roche
Phase 2
534
Gda?sk, Gliwice, Późna, Warsaw
2015-11-19
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Bialystok, Bydgoszcz, Gdynia, Gliwice, Kielce, Lodz, Olsztyn, Poznan
2015-11-19
Active, closed
AstraZeneca
Phase 3
1,126
Gdansk, Gdynia, Gliwice, Olsztyn, Otwock, Szczecin, Warsaw
2015-11-02
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Gliwice, Wroclaw
2015-03-05
Active, closed
Exelixis
Phase 4
247
Poznan, Gliwice
2015-02-25
Rows per page Showing 1–121 of 121
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-poland/city/gliwice

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,709 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 121 of those studies with a site in Gliwice.

How many clinical trials are recruiting in Gliwice?

67 of the 121 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 53 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gliwice), 121 studies
PhaseStudiesRecruitingShare
Phase 3723659.5%
Phase 2201116.5%
Phase 2/31078.3%
Phase 1/2665%
Not applicable433.3%
Phase 1423.3%
Phase 4312.5%
Observational211.7%

Most active sponsors

Lead sponsors with the most studies (Gliwice)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2010
Maria Sklodowska-Curie National Research Institute of Oncology117
AstraZeneca108
Hoffmann-La Roche93
Janssen Research & Development, LLC75
Novartis Pharmaceuticals61
Exelixis41
Amgen32
GlaxoSmithKline33
Astellas Pharma Global Development, Inc.22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.